RSCM
TARA icon

Rock Springs Capital Management’s Protara Therapeutics TARA Stock Holding History

Rock Springs Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-693,542
Closed -$6.75M – 162
2021
Q2 		$6.75M Buy
693,542
+3,600
+0.5% +$40.8K 0.13% 129
2021
Q1 		$10.9M Buy
689,942
+46,742
+7% +$867K 0.24% 105
2020
Q4 		$15.6M Sell
643,200
-422
-0.1% -$9.1K 0.33% 92
2020
Q3 		$10.8M Buy
+643,622
New +$14.9M 0.27% 99

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rock Springs Capital Management's TARA Position: Q3 2021 in Review

Rock Springs Capital Management sold out of Protara Therapeutics (TARA) in Q3 2021, closing a stake of 693,542 shares — an estimated $6.75M sold.

Rock Springs Capital Management first reported a position in TARA in Q3 2020 and held it in 4 quarters. The position peaked at $15.6M in Q4 2020. 36 funds tracked by Wall St. Rank hold TARA as of Q3 2021.

  • Rock Springs Capital Management reported no remaining Protara Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Rock Springs Capital Management sold 693,542 Protara Therapeutics shares in Q3 2021, an estimated $6.75M.
  • Rock Springs Capital Management first reported a position in Protara Therapeutics in Q3 2020 and held it in 4 quarters.
  • Rock Springs Capital Management's Protara Therapeutics position peaked at $15.6M in Q4 2020.
  • 36 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2021.

Based on Rock Springs Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.